Teva Pharm Company Profile
What is the competitive landscape for TEVA PHARM
TEVA PHARM has three hundred and thirty-eight approved drugs.
There are nine US patents protecting TEVA PHARM drugs. There are forty-four tentative approvals on TEVA PHARM drugs.
Summary for Teva Pharm
| US Patents: | 9 |
| Tradenames: | 283 |
| Ingredients: | 274 |
| NDAs: | 338 |
| Patent Litigation for Teva Pharm: | See patent lawsuits for Teva Pharm |
| PTAB Cases with Teva Pharm as petitioner: | See PTAB cases with Teva Pharm as petitioner |
Drugs and US Patents for Teva Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa Inc | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | dapagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 211583-001 | Apr 6, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms Usa | PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE | metformin hydrochloride; pioglitazone hydrochloride | TABLET;ORAL | 091155-001 | Mar 10, 2014 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Pharms | VALACYCLOVIR HYDROCHLORIDE | valacyclovir hydrochloride | TABLET;ORAL | 077655-002 | May 24, 2010 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 6,620,847 | ⤷ Start Trial |
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-002 | Jan 27, 2017 | 6,701,917 | ⤷ Start Trial |
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-002 | Jan 27, 2017 | 6,871,646 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
International Patents for Teva Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101507648 | ⤷ Start Trial |
| Japan | 2005508896 | ⤷ Start Trial |
| China | 112891688 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1506211 | 42/2014 | Austria | ⤷ Start Trial | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON UND METFORMIN UND EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/13/900 (MITTEILUNG) 20140121 |
| 3150586 | PA2020508 | Lithuania | ⤷ Start Trial | PRODUCT NAME: KOBICISTANAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS, DARUNAVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS, YPAC DARUNAVIRO ETANOLATAS, IR EMTRICITABINAS, ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/17/1225 20170921 |
| 1632232 | 122016000110 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION VON RILPIVIRINHYDROCHLORID ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
